Last reviewed · How we verify
Polypeptides
Polypeptides is a Small molecule drug developed by Ryazan State Medical University. It is currently in Phase 1 development. Also known as: vascular polypeptides Slavinorm®, a derivative from cattle vessels.
Polypeptides are longer, continuous, unbranched chains of amino acids linked by peptide bonds, typically with a molecular mass of 10,000 Da or more. They are also known as proteins, and can be found in various forms, including Amylin (Pramlintide), Pancreatic Polypeptide (PP), and PACAP38, which have been studied in clinical trials for conditions such as Migraine Without Aura, Obesity & Overweight, Spinal Cord Injuries, and Type 2 Diabetes.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Polypeptides |
|---|---|
| Also known as | vascular polypeptides Slavinorm®, a derivative from cattle vessels |
| Sponsor | Ryazan State Medical University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US (PHASE2)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
- Growth Hormone Administration and the Human Immune System (PHASE1)
- Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load (PHASE1)
- A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese (PHASE1)
- Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients (PHASE4)
- Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polypeptides CI brief — competitive landscape report
- Polypeptides updates RSS · CI watch RSS
- Ryazan State Medical University portfolio CI
Frequently asked questions about Polypeptides
What is Polypeptides?
Who makes Polypeptides?
Is Polypeptides also known as anything else?
What development phase is Polypeptides in?
Related
- Manufacturer: Ryazan State Medical University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: vascular polypeptides Slavinorm®, a derivative from cattle vessels
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing